Share price & Turnover
Calendar
2025-10-28 | Quarterly Report 2025-Q3 |
2025-07-18 | Quarterly Report 2025-Q2 |
2025-04-23 | Quarterly Report 2025-Q1 |
2025-04-03 | Annual General meeting |
2025-02-25 | Year-end Report 2024 |
2024-10-29 | Quarterly Report 2024-Q3 |
2024-10-15 | Ex-date Semi-Annual Dividend ORNAV 0.81 |
2024-10-15 | Ex-date Semi-Annual Dividend ORNBV 0.81 |
2024-08-08 | Quarterly Report 2024-Q2 |
2024-04-25 | Quarterly Report 2024-Q1 |
2024-03-21 | Ex-date Semi-Annual Dividend ORNBV 0.81 |
2024-03-21 | Ex-date Semi-Annual Dividend ORNAV 0.81 |
2024-03-20 | Annual General meeting |
2024-02-13 | Year-end Report 2023 |
2023-10-26 | Quarterly Report 2023-Q3 |
2023-07-17 | Quarterly Report 2023-Q2 |
2023-04-27 | Quarterly Report 2023-Q1 |
2023-03-23 | Ex-date Ordinary Dividend ORNBV 1.60 EUR |
2023-03-23 | Ex-date Ordinary Dividend ORNAV 1.60 EUR |
2023-03-22 | Annual General meeting |
2023-02-09 | Year-end Report 2022 |
2022-10-20 | Quarterly Report 2022-Q3 |
2022-07-15 | Quarterly Report 2022-Q2 |
2022-04-28 | Quarterly Report 2022-Q1 |
2022-03-24 | Ex-date Ordinary Dividend ORNBV 1.50 EUR |
2022-03-24 | Ex-date Ordinary Dividend ORNAV 1.50 EUR |
2022-03-23 | Annual General meeting |
2022-02-10 | Year-end Report 2021 |
2021-10-20 | Quarterly Report 2021-Q3 |
2021-07-19 | Quarterly Report 2021-Q2 |
2021-04-27 | Quarterly Report 2021-Q1 |
2021-03-26 | Ex-date Ordinary Dividend ORNAV 1.50 EUR |
2021-03-26 | Ex-date Ordinary Dividend ORNBV 1.50 EUR |
2021-03-25 | Annual General meeting |
2021-02-09 | Year-end Report 2020 |
2020-10-21 | Quarterly Report 2020-Q3 |
2020-07-17 | Quarterly Report 2020-Q2 |
2020-05-07 | Ex-date Ordinary Dividend ORNAV 1.50 EUR |
2020-05-07 | Ex-date Ordinary Dividend ORNBV 1.50 EUR |
2020-05-06 | Annual General meeting |
2020-04-28 | Quarterly Report 2020-Q1 |
2020-03-26 | Ex-date Ordinary Dividend ORNBV 1.50 EUR |
2020-02-05 | Year-end Report 2019 |
2019-10-23 | Quarterly Report 2019-Q3 |
2019-07-17 | Quarterly Report 2019-Q2 |
2019-04-25 | Quarterly Report 2019-Q1 |
2019-03-27 | Ex-date Ordinary Dividend ORNAV 1.50 EUR |
2019-03-27 | Ex-date Ordinary Dividend ORNBV 1.50 EUR |
2019-03-26 | Annual General meeting |
2019-02-06 | Year-end Report 2018 |
2018-10-24 | Quarterly Report 2018-Q3 |
2018-07-18 | Quarterly Report 2018-Q2 |
2018-04-24 | Quarterly Report 2018-Q1 |
2018-03-21 | Ex-date Ordinary Dividend ORNAV 1.45 EUR |
2018-03-21 | Ex-date Ordinary Dividend ORNBV 1.45 EUR |
2018-03-20 | Annual General meeting |
2018-02-07 | Year-end Report 2017 |
2017-10-26 | Quarterly Report 2017-Q3 |
2017-07-19 | Quarterly Report 2017-Q2 |
2017-05-18 | Capital Market Day 2017 |
2017-04-26 | Quarterly Report 2017-Q1 |
2017-03-23 | Ex-date Bonus Dividend ORNAV 0.2 |
2017-03-23 | Ex-date Ordinary Dividend ORNBV 1.35 EUR |
2017-03-23 | Ex-date Ordinary Dividend ORNAV 1.35 EUR |
2017-03-23 | Ex-date Bonus Dividend ORNBV 0.2 |
2017-03-22 | Annual General meeting |
2017-02-08 | Year-end Report 2016 |
2016-10-25 | Quarterly Report 2016-Q3 |
2016-07-19 | Quarterly Report 2016-Q2 |
2016-04-27 | Quarterly Report 2016-Q1 |
2016-03-23 | Ex-date Ordinary Dividend ORNBV 1.30 EUR |
2016-03-23 | Ex-date Ordinary Dividend ORNAV 1.30 EUR |
2016-03-22 | Annual General meeting |
2016-02-02 | Year-end Report 2015 |
2015-10-27 | Quarterly Report 2015-Q3 |
2015-07-28 | Quarterly Report 2015-Q2 |
2015-05-26 | Capital Market Day 2015 |
2015-04-29 | Quarterly Report 2015-Q1 |
2015-03-25 | Ex-date Ordinary Dividend ORNAV 1.30 EUR |
2015-03-25 | Ex-date Ordinary Dividend ORNBV 1.30 EUR |
2015-03-24 | Annual General meeting |
2015-02-04 | Year-end Report 2014 |
2014-10-21 | Quarterly Report 2014-Q3 |
2014-07-29 | Quarterly Report 2014-Q2 |
2014-04-29 | Quarterly Report 2014-Q1 |
2014-03-26 | Ex-date Ordinary Dividend ORNBV 1.25 EUR |
2014-03-26 | Ex-date Ordinary Dividend ORNAV 1.25 EUR |
2014-03-25 | Annual General meeting |
2014-02-04 | Year-end Report 2013 |
2013-10-22 | Quarterly Report 2013-Q3 |
2013-07-30 | Quarterly Report 2013-Q2 |
2013-04-23 | Quarterly Report 2013-Q1 |
2013-03-20 | Ex-date Ordinary Dividend ORNBV 1.30 EUR |
2013-03-20 | Ex-date Ordinary Dividend ORNAV 1.30 EUR |
2013-03-19 | Annual General meeting |
2013-02-05 | Year-end Report 2012 |
2012-10-23 | Quarterly Report 2012-Q3 |
2012-07-31 | Quarterly Report 2012-Q2 |
2012-05-24 | Capital Market Day 2012 |
2012-04-24 | Quarterly Report 2012-Q1 |
2012-03-21 | Ex-date Ordinary Dividend ORNBV 1.30 EUR |
2012-03-21 | Ex-date Bonus Dividend ORNBV 0.12 |
2012-03-21 | Ex-date Bonus Dividend ORNAV 0.12 |
2012-03-21 | Ex-date Ordinary Dividend ORNAV 1.30 EUR |
2012-03-20 | Annual General meeting |
2012-02-07 | Year-end Report 2011 |
2011-10-25 | Quarterly Report 2011-Q3 |
2011-08-02 | Quarterly Report 2011-Q2 |
2011-04-27 | Quarterly Report 2011-Q1 |
2011-04-01 | Ex-date Ordinary Dividend ORNAV 1.20 EUR |
2011-04-01 | Ex-date Bonus Dividend ORNBV 0.06 |
2011-04-01 | Ex-date Ordinary Dividend ORNBV 1.20 EUR |
2011-04-01 | Ex-date Bonus Dividend ORNAV 0.06 |
2011-03-31 | Annual General meeting |
2011-02-09 | Year-end Report 2010 |
2010-10-26 | Quarterly Report 2010-Q3 |
2010-08-10 | Quarterly Report 2010-Q2 |
2010-04-27 | Quarterly Report 2010-Q1 |
2010-03-25 | Ex-date Bonus Dividend ORNAV 0.1 |
2010-03-25 | Ex-date Bonus Dividend ORNBV 0.1 |
2010-03-25 | Ex-date Ordinary Dividend ORNBV 1.00 EUR |
2010-03-25 | Ex-date Ordinary Dividend ORNAV 1.00 EUR |
2009-03-24 | Ex-date Ordinary Dividend ORNBV 0.95 EUR |
2009-03-24 | Ex-date Ordinary Dividend ORNAV 0.95 EUR |
2008-03-26 | Ex-date Ordinary Dividend ORNBV 1.00 EUR |
2007-04-03 | Ex-date Ordinary Dividend ORNAV 1.00 EUR |
2007-04-03 | Ex-date Ordinary Dividend ORNBV 1.00 EUR |
2006-03-22 | Ex-date Ordinary Dividend ORNBV 0.85 EUR |
2005-03-22 | Ex-date Ordinary Dividend ORNBV 0.55 EUR |
2005-03-22 | Ex-date Ordinary Dividend ORNAV 0.55 EUR |
2004-09-15 | Ex-date Bonus Dividend ORNAV 2.14 |
2004-09-15 | Ex-date Bonus Dividend ORNBV 2.14 |
2004-03-23 | Ex-date Ordinary Dividend ORNAV 1.60 EUR |
2004-03-23 | Ex-date Ordinary Dividend ORNBV 1.60 EUR |
2003-12-12 | Ex-date Bonus Dividend ORNBV 1.5 |
2003-12-12 | Ex-date Bonus Dividend ORNAV 1.5 |
2003-03-23 | Ex-date Ordinary Dividend ORNBV 0.93 EUR |
2003-03-23 | Ex-date Ordinary Dividend ORNAV 0.93 EUR |
2002-04-16 | Ex-date Ordinary Dividend ORNAV 1.10 EUR |
2002-04-16 | Ex-date Ordinary Dividend ORNBV 1.10 EUR |
2001-03-30 | Ex-date Ordinary Dividend ORNBV 1.20 EUR |
2001-03-30 | Ex-date Ordinary Dividend ORNAV 1.20 EUR |
2000-03-31 | Ex-date Ordinary Dividend ORNBV 1.18 EUR |
2000-03-31 | Ex-date Ordinary Dividend ORNAV 1.18 EUR |
1999-07-28 | Ex-date Bonus Dividend ORNAV 13.46 |
1999-07-28 | Ex-date Bonus Dividend ORNBV 13.46 |
1999-04-09 | Ex-date Ordinary Dividend ORNAV 6.50 EUR |
1999-04-09 | Ex-date Ordinary Dividend ORNBV 6.50 EUR |
1998-04-21 | Ex-date Ordinary Dividend ORNBV 7.50 EUR |
1998-04-21 | Ex-date Ordinary Dividend ORNAV 7.50 EUR |
1997-04-22 | Ex-date Ordinary Dividend ORNBV 5.00 EUR |
1997-04-22 | Ex-date Ordinary Dividend ORNAV 5.00 EUR |
1996-04-23 | Ex-date Ordinary Dividend ORNAV 4.00 EUR |
1996-04-23 | Ex-date Ordinary Dividend ORNBV 4.00 EUR |
Description
Country | Finland |
---|---|
List | Large Cap Helsinki |
Sector | Health care |
Industry | Drugs & Trade |
ORION CORPORATION
INSIDE INFORMATION / STOCK EXCHANGE RELEASE
17 FEBRUARY 2022 at 23.32 EET
Orion’s collaboration partner Bayer upgrades estimate on Nubeqa®’s peak sales potential
Orion’s collaboration partner Bayer has upgraded estimate on Nubeqa®’s (darolutamide) peak sales potential. According to Bayer’s new estimate, Nubeqa’s annual global peak sales could exceed EUR 3 billion. Earlier Bayer has anticipated that Nubeqa’s annual global peak sales could exceed EUR 1 billion.
Bayer holds global commercial rights to darolutamide and Orion is entitled to receive annually tiered royalties on global darolutamide sales. The total annual royalty rate is approximately 20% including product sales to Bayer. Initially the total annual royalty rate will be slightly lower, and as sales increase, the total annual royalty rate will increase. Orion manufactures the product for global markets and co-promotes the product in Europe with Bayer.
In addition to royalties, Orion is entitled to receive progressive one-off milestone payments from Bayer that may total EUR 280 million, depending on the future sales development of Nubeqa.
Orion Corporation
Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Tuukka Hirvonen, Orion Investor Relations
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.